The Figure shows the curves for the percentage of patients with an primary outcome event (stroke or systemic embolism) per time.[99] The result was a hazard ratio of 0.79 with apixaban, p=0.011.  These data are similar to the results with dabigatran in RE-LY,[96] which are shown in a following Figure.

 Reiffel JA. Am J Med 2013; 126: 00-00.